Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Kidney International

Volumn 89, Issue 3, 2016, Pages 701-711

  Greenbaum, Larry A ^a   Fila, Marc ^b   Ardissino, Gianluigi ^c   Al Akash, Samhar I ^d   Evans, Jonathan ^e   Henning, Paul ^f   Lieberman, Kenneth V ^g   Maringhini, Silvio ^h   Pape, Lars ⁱ   Rees, Lesley ^j   Van De Kar, Nicole C A J ^k   Vande Walle, Johan ^l   Ogawa, Masayo ^m   Bedrosian, Camille L ^m   Licht, Christoph ⁿ  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Driscoll Childrens Hospital   (United States)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^g HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^h G Di Cristina Children's Hospital   (Italy)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m ALEXION PHARMACEUTICALS   (United States)

ⁿ HOSPITAL FOR SICK CHILDREN   (Canada)

more..

Author keywords

aHUS; children; eculizumab; kidney disease; pediatric; thrombotic microangiopathy

Indexed keywords

CREATININE; ECULIZUMAB; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE RESPIRATORY FAILURE; ADOLESCENT; AREA UNDER THE CURVE; BONE MARROW DEPRESSION; CHILD; CHILD CARE; CONFERENCE PAPER; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INFANT; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; MENINGOCOCCOSIS; MINIMUM PLASMA CONCENTRATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLASMA TRANSFUSION; PLASMAPHERESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; RHINOPHARYNGITIS; SCHOOL CHILD; SYMPTOMATOLOGY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING; WRIST FRACTURE; AGE; ATYPICAL HEMOLYTIC UREMIC SYNDROME; AUSTRALIA; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DRUG EFFECTS; EUROPE; HEMODIALYSIS; IMMUNOLOGY; MULTICENTER STUDY; NORTH AMERICA; PLASMA EXCHANGE; TIME FACTOR;

ADOLESCENT; AGE FACTORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; AUSTRALIA; CHILD; CHILD, PRESCHOOL; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; EUROPE; FEMALE; HUMANS; INFANT; MALE; NORTH AMERICA; PLASMA EXCHANGE; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84964561130     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2015.11.026     Document Type: Conference Paper

References (52)

1. M. Noris, and G. Remuzzi Atypical hemolytic-uremic syndrome N Engl J Med 361 2009 1676 1687
2. P.F. Zipfel, S. Heinen, and C. Skerka Thrombotic microangiopathies: new insights and new challenges Curr Opin Nephrol Hypertens 19 2010 372 378
3. K. Benz, and K. Amann Thrombotic microangiopathy: new insights Curr Opin Nephrol Hypertens 19 2010 242 247
4. M. Noris, J. Caprioli, E. Bresin, and et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype Clin J Am Soc Nephrol 5 2010 1844 1859
5. V. Fremeaux-Bacchi, F. Fakhouri, A. Garnier, and et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults Clin J Am Soc Nephrol 8 2013 554 562
6. T.K. Maga, C.J. Nishimura, A.E. Weaver, and et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome Hum Mutat 31 2010 E1445 E1460
7. M. Delvaeye, M. Noris, A. De Vriese, and et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome N Engl J Med 361 2009 345 357
8. F. Bu, T. Maga, N.C. Meyer, and et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome J Am Soc Nephrol 25 2014 55 64
9. M. Lemaire, V. Fremeaux-Bacchi, F. Schaefer, and et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome Nat Genet 45 2013 531 536
10. J. Caprioli, M. Noris, S. Brioschi, and et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Blood 108 2006 1267 1279
11. A.L. Sellier-Leclerc, V. Fremeaux-Bacchi, M.A. Dragon-Durey, and et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome J Am Soc Nephrol 18 2007 2392 2400
12. C. Loirat, M. Noris, and V. Fremeaux-Bacchi Complement and the atypical hemolytic uremic syndrome in children Pediatr Nephrol 23 2008 1957 1972
13. J. Zuber, F. Fakhouri, L.T. Roumenina, and et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat Rev Nephrol 8 2012 643 657
14. M. Malina, A. Gulati, A. Bagga, and et al. Peripheral gangrene in children with atypical hemolytic uremic syndrome Pediatrics 131 2013 e331 e335
15. C. Loirat, M.A. Macher, M. Elmaleh-Berges, and et al. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation Nephrol Dial Transplant 25 2010 3421 3425
16. R. Vilalta, E. Lara, A. Madrid, and et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome Pediatr Nephrol 27 2012 2323 2326
17. M.A. Dragon-Durey, S.K. Sethi, A. Bagga, and et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome J Am Soc Nephrol 21 2010 2180 2187
18. L.M. Geerdink, D. Westra, J.A. van Wijk, and et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics Pediatr Nephrol 27 2012 1283 1291
19. C. Loirat, A. Garnier, A.L. Sellier-Leclerc, and et al. Plasmatherapy in atypical hemolytic uremic syndrome Semin Thromb Hemost 36 2010 673 681
20. S. Johnson, J. Stojanovic, G. Ariceta, and et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome Pediatr Nephrol 29 2014 1967 1978
21. US Food and Drug Administration: Soliris (eculizumab) [prescribing information] 2014 Alexion Pharmaceuticals, Inc. Cheshire, CT
22. European Medicines Agency: Soliris (eculizumab) [summary of product characteristics] 2014 Alexion Europe SAS Paris, France
23. F. Fakhouri, Y. Delmas, F. Provot, and et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases Am J Kidney Dis 63 2014 40 48
24. C.M. Legendre, C. Licht, P. Muus, and et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 2013 2169 2181
25. C. Licht, L.A. Greenbaum, P. Muus, and et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies Kidney Int 87 2015 1061 1073
26. S.I. Al-Akash, P.S. Almond, V.H. Savell Jr., and et al. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation Pediatr Nephrol 26 2011 613 619
27. A.L. Lapeyraque, V. Fremeaux-Bacchi, and P. Robitaille Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome Pediatr Nephrol 26 2011 621 624
28. S. Tschumi, M. Gugger, B.S. Bucher, and et al. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings Pediatr Nephrol 26 2011 2085 2088
29. F.S. Cayci, N. Cakar, V.S. Hancer, and et al. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation Pediatr Nephrol 27 2012 2327 2331
30. E.M. Dorresteijn, N.C. van de Kar, and K. Cransberg Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count Pediatr Nephrol 27 2012 1193 1195
31. Z.D. Bekassy, A.C. Kristoffersson, M. Cronqvist, and et al. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions Nephrol Dial Transplant 28 2013 2899 2907
32. N. Besbas, B. Gulhan, D. Karpman, and et al. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab Pediatr Nephrol 28 2013 155 158
33. R.D. Gilbert, D.J. Fowler, E. Angus, and et al. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B Pediatr Nephrol 28 2013 1315 1318
34. K. Gulleroglu, K. Fidan, V.S. Hancer, and et al. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab Pediatr Nephrol 28 2013 827 830
35. E. Roman-Ortiz, O.S. Mendizabal, S. Pinto, and et al. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene Pediatr Nephrol 29 2014 149 153
36. R.A. Gruppo, and R.P. Rother Eculizumab for congenital atypical hemolytic-uremic syndrome N Engl J Med 360 2009 544 546
37. J.C. Davin, V. Gracchi, A. Bouts, and et al. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation Am J Kidney Dis 55 2010 708 711
38. D. Simonetti, R. Gruppo, N. Rodig, and et al. Eculizumab therapy for atypical hemolytic uremic syndrome in pediatric patients: efficacy and safety outcomes from a retrospective study [abstract 0396] Haematologica 96 suppl 2 2011 165
39. R. Vilalta, S. Al-Akash, J. Davin, and et al. Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: efficacy and safety outcomes of a retrospective study [abstract 1155] Haematologica 97 suppl 1 2012 479
40. V. Chatelet, V. Fremeaux-Bacchi, T. Lobbedez, and et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome Am J Transplant 9 2009 2644 2645
41. C.J. Mache, B. Acham-Roschitz, V. Fremeaux-Bacchi, and et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome Clin J Am Soc Nephrol 4 2009 1312 1316
42. F. Fakhouri, M. Hourmant, J.M. Campistol, and et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult atypical hemolytic uremic syndrome (aHUS) patients (Pts) [abstract FR-OR057] J Am Soc Nephrol 24 2013 49A 50A
43. M. Christmann, M. Hansen, C. Bergmann, and et al. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome Pediatrics 133 2014 e1759 e1763
44. J.M. Campistol, M. Arias, G. Ariceta, and et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document Nefrologia 33 2013 27 45
45. C. Loirat, F. Fakhouri, G. Ariceta, and et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children Pediatr Nephrol 31 2016 15 39
46. W. Hayes, S. Tschumi, S.C. Ling, and et al. Eculizumab hepatotoxicity in pediatric aHUS Pediatr Nephrol 30 2015 775 781
47. G.J. Schwartz, A. Munoz, M.F. Schneider, and et al. New equations to estimate GFR in children with CKD J Am Soc Nephrol 20 2009 629 637
48. J.S. Lai, D. Cella, M.J. Kupst, and et al. Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F) J Pediatr Hematol Oncol 29 2007 471 479
49. FACIT.org. FACIT measurement system questionnaires. Available at: http://www.facit.org/FACITOrg/Questionnaires. Accessed July 17, 2014.
50. C.S. Rinder, H.M. Rinder, B.R. Smith, and et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation J Clin Invest 96 1995 1564 1572
51. European Medicines Agency. Soliris: EPAR - scientific discussion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000791/WC500054212.pdf. Accessed May 20, 2014.
52. European Medicines Agency. Soliris (eculizumab): EU assessment report. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000791/WC500119185.pdf. Accessed October 14, 2014.